Macrophages mediate acute kidney allograft rejection via a toll-like receptor 4-dependent mechanism

Qixia Shen1, Tingting Zhu2, Sijing Yan2

  • 1Department of Nephrology, Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; Institute of Nephrology, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang Province, People's Republic of China; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China.

Kidney International
|October 1, 2025
PubMed
Abstract

Insights

Macrophages mediate acute renal allograft rejection (RAR) through toll-like receptor 4 (TLR4) and hypoxia-inducible factor 1-alpha (HIF1α). Targeting this pathway reduces inflammation and may prevent chronic injury.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Renal Medicine

Background:

  • Macrophages are key players in acute renal allograft rejection (RAR).
  • The specific mechanisms by which macrophages contribute to RAR are not fully understood.
  • Toll-like receptor 4 (TLR4) signaling is implicated in inflammatory processes.

Purpose of the Study:

  • To investigate the role of myeloid cell TLR4 in mediating acute RAR.
  • To elucidate the downstream molecular pathways involved in TLR4-dependent RAR.
  • To evaluate the therapeutic potential of targeting the TLR4/HIF1α axis in RAR.

Main Methods:

  • Acute RAR was induced in myeloid cell-specific TLR4 knockout mice.
  • Rejection severity was assessed using Banff scores, immune cell infiltration, and kidney function.
  • Single cell RNA sequencing (scRNA-seq) and pharmacological HIF1α inhibition were employed to study mechanisms.

Main Results:

  • Myeloid TLR4 disruption significantly suppressed acute RAR, improving kidney function and reducing inflammation.
  • scRNA-seq identified HIF1α as a critical downstream target of TLR4 in macrophages.
  • Targeting TLR4/HIF1α reduced pro-inflammatory macrophages, suppressed antigen presentation, and modulated T cell responses, also ameliorating fibrosis.

Conclusions:

  • Macrophages mediate acute RAR via a TLR4/HIF1α-dependent pathway.
  • Targeting TLR4/HIF1α signaling represents a potential therapeutic strategy for acute RAR.
  • This approach may also offer benefits in mitigating chronic allograft injury and fibrosis.